A Multi-dose Phase II Trial of Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism
- Focus Biomarker; Pharmacodynamics
- 23 Jan 2020 Status changed from active, no longer recruiting to completed.
- 28 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 05 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.